Disease · MONDO_0021223
digestive system neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. digestive system neoplasm. Diseases, record MONDO_0021223. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021223
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
GI neoplasm, GI system neoplasm, GI system tumor, GI system tumour, GI tumor, GI tumour, digestive neoplasm, digestive system neoplasm (disease), digestive system tumor, digestive system tumour, digestive tumor, digestive tumour, gastrointestinal neoplasm, gastrointestinal system neoplasm, gastrointestinal system tumor, gastrointestinal system tumour, gastrointestinal tumor, gastrointestinal tumour, neoplasm of GI system, neoplasm of digestive system, neoplasm of gastrointestinal system, neoplasm of the GI system, neoplasm of the digestive system, neoplasm of the gastrointestinal system, tumor of GI system, tumor of digestive system, tumor of gastrointestinal system, tumor of the GI system, tumor of the digestive system, tumor of the gastrointestinal system, tumour of GI system, tumour of digestive system, tumour of gastrointestinal system, tumour of the GI system, tumour of the digestive system, tumour of the gastrointestinal system
- Open Targets
Drugs59
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CATEQUENTINIB | CHEMBL4303201 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALECTINIB | CHEMBL1738797 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALPELISIB | CHEMBL2396661 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BRIGATINIB | CHEMBL3545311 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| COBIMETINIB | CHEMBL2146883 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ENTRECTINIB | CHEMBL1983268 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ERLOTINIB | CHEMBL553 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IPATASERTIB | CHEMBL2177390 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 59
See all 59 drugsTargets96
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 4 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 4 | Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| ALK | ALK tyrosine kinase receptor | 3 | ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | Phase 2 | https://conductscience.org/library/genes/238 | Drugs and targets |
| RET | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET | 3 | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor | Phase 2 | https://conductscience.org/library/genes/5979 | Drugs and targets |
| TUBA1A | Tubulin | 3 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 3 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 3 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 3 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 3 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/112714 | Drugs and targets |
1 to 10 of 96
See all 96 targetsTrials21
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03663712 | Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies | Phase 1 | 28 | 2024-11-20 | Peritoneal Surface Malignancy | TALIMOGENE LAHERPAREPVEC | Its record names the disease | ClinicalTrials.gov |
| NCT04591431 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | Phase 2 | 400 | Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer | ALECTINIB, ALPELISIB, ATEZOLIZUMAB, BRIGATINIB, COBIMETINIB, ENTRECTINIB, ERLOTINIB, EVEROLIMUS, IPATASERTIB, IPILIMUMAB, ITACITINIB, LAPATINIB, NIVOLUMAB, PALBOCICLIB, PEMIGATINIB, PERTUZUMAB, PONATINIB, PRALSETINIB, SELPERCATINIB, TALAZOPARIB, TEPOTINIB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, VEMURAFENIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05437497 | Safety and Efficacy Evaluation of Remimazolam for Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy | Not applicable | 264 | Endoscopic Ultrasonography-guided Fine Needle Aspiration, Sedation Complication, Remimazolam | PROPOFOL, REMIMAZOLAM | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04207463 | A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors | Phase 2 | 150 | Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors | CATEQUENTINIB, PENPULIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | Phase 1/2 | 122 | Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma | ATEZOLIZUMAB, GEMCITABINE, PELAREOREP | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05552729 | Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors | Phase 1/2 | 114 | Gastrointestinal Neoplasms, Cognitive Impairment | ERGOCALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03977077 | Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol | Not applicable | 100 | Advanced Gastrointestinal Tumors | PACLITAXEL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02675946 | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Phase 1 | 72 | Solid Tumors, GI Cancer | CETUXIMAB, ENCORAFENIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01916447 | A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. | Phase 1 | 65 | Advanced Gastrointestinal Tumors | BEVACIZUMAB, IRINOTECAN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04611711 | Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors | Phase 1/2 | 60 | Patients With Digestive System Tumors Resistant to PD-1 Inhibitors | BENMELSTOBART, CATEQUENTINIB, DECITABINE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 21
See all 21 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021223
GET https://conductscience.org/api/diseases/v1/MONDO_0021223/drugs?page=2